[go: up one dir, main page]

BR9406007A - Construção de DNA, vacina de polinucleotídeos, vetor, processos para proteger contra infecção por vírus influenza humano, para usar um gene de vírus influenza, para induzir respostas imunes contra infecção ou doença provocada por cepas de vírus influenza, composição de construções de ácido nucleico e uso de um gene de vírus influenza humano - Google Patents

Construção de DNA, vacina de polinucleotídeos, vetor, processos para proteger contra infecção por vírus influenza humano, para usar um gene de vírus influenza, para induzir respostas imunes contra infecção ou doença provocada por cepas de vírus influenza, composição de construções de ácido nucleico e uso de um gene de vírus influenza humano

Info

Publication number
BR9406007A
BR9406007A BR9406007A BR9406007A BR9406007A BR 9406007 A BR9406007 A BR 9406007A BR 9406007 A BR9406007 A BR 9406007A BR 9406007 A BR9406007 A BR 9406007A BR 9406007 A BR9406007 A BR 9406007A
Authority
BR
Brazil
Prior art keywords
influenza virus
infection
virus gene
human influenza
gene
Prior art date
Application number
BR9406007A
Other languages
English (en)
Inventor
John J Donnelly
Varavani J Dwarki
Margaret A Liu
Donna L Montgomery
Suezanne E Parker
John W Shiver
Jeffrey B Ulmer
Original Assignee
Merck & Co Inc
Vical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Vical Inc filed Critical Merck & Co Inc
Publication of BR9406007A publication Critical patent/BR9406007A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BR9406007A 1993-03-18 1994-03-14 Construção de DNA, vacina de polinucleotídeos, vetor, processos para proteger contra infecção por vírus influenza humano, para usar um gene de vírus influenza, para induzir respostas imunes contra infecção ou doença provocada por cepas de vírus influenza, composição de construções de ácido nucleico e uso de um gene de vírus influenza humano BR9406007A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3238393A 1993-03-18 1993-03-18
US8998593A 1993-07-08 1993-07-08
PCT/US1994/002751 WO1994021797A1 (en) 1993-03-18 1994-03-14 Nucleic acid pharmaceuticals

Publications (1)

Publication Number Publication Date
BR9406007A true BR9406007A (pt) 1996-01-02

Family

ID=26708344

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9406007A BR9406007A (pt) 1993-03-18 1994-03-14 Construção de DNA, vacina de polinucleotídeos, vetor, processos para proteger contra infecção por vírus influenza humano, para usar um gene de vírus influenza, para induzir respostas imunes contra infecção ou doença provocada por cepas de vírus influenza, composição de construções de ácido nucleico e uso de um gene de vírus influenza humano

Country Status (22)

Country Link
EP (1) EP0620277A1 (pt)
JP (2) JP2812352B2 (pt)
CN (1) CN1119458A (pt)
AU (1) AU676258B2 (pt)
BG (1) BG63126B1 (pt)
BR (1) BR9406007A (pt)
CA (1) CA2119175A1 (pt)
CZ (1) CZ290315B6 (pt)
DZ (1) DZ1759A1 (pt)
FI (1) FI954329L (pt)
HR (1) HRP940175A2 (pt)
HU (1) HUT73397A (pt)
IL (1) IL108915A0 (pt)
NO (1) NO953649L (pt)
NZ (1) NZ263680A (pt)
PL (1) PL178626B1 (pt)
RO (1) RO117710B1 (pt)
SI (1) SI9420014A (pt)
SK (1) SK114295A3 (pt)
UA (1) UA42715C2 (pt)
WO (1) WO1994021797A1 (pt)
YU (1) YU12894A (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US6911216B1 (en) 1994-10-12 2005-06-28 Genzyme Corporation Targeted delivery via biodegradable polymers
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
DE19512142A1 (de) * 1995-03-31 1996-10-02 Immuno Ag Infektiöser cDNA-Klon des Tick-Borne Enzephalitis (TBE)-Virus, davon abgeleiteter rekombinanter Impfstoff und Herstellung desselben sowie ein pharmazeutisches Produkt, das eine replizierbare Nukleinsäure enthält
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6083925A (en) 1995-06-07 2000-07-04 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6017897A (en) * 1995-06-07 2000-01-25 Pasteur Merieux Connaught Canada Nucleic acid respiratory syncytial virus vaccines
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
FR2751225B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
US6204250B1 (en) 1996-11-22 2001-03-20 The Mount Sinai Medical Center Of The City Of New York Immunization of infants
CA2280839A1 (en) * 1997-02-14 1998-08-20 Merck & Co., Inc. Polynucleotide vaccine formulations
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
CA2340330A1 (en) 1998-08-20 2000-03-02 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein c of chlamydia
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6881723B1 (en) 1998-11-05 2005-04-19 Powderject Vaccines, Inc. Nucleic acid constructs
US7618797B2 (en) 1998-12-22 2009-11-17 Pfizer Inc Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7691389B2 (en) 1998-12-22 2010-04-06 Pfizer Inc Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7022320B1 (en) 1999-02-09 2006-04-04 Powderject Vaccines, Inc. Mycobacterium tuberculosis immunization
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
JP2001151698A (ja) * 1999-09-10 2001-06-05 Nichiko Pharmaceutical Co Ltd インフルエンザワクチン
ATE391726T1 (de) 1999-10-22 2008-04-15 Sanofi Pasteur Ltd Modifiziertes gp100 und dessen verwendung
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
EP1792995A3 (en) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia secretory locus orf and uses thereof
EP1282702B1 (en) 2000-05-10 2006-11-29 Sanofi Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
CA2566355C (en) 2004-05-18 2014-04-15 Vical Incorporated Influenza virus vaccine composition and methods of use
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
WO2008150998A1 (en) * 2007-05-31 2008-12-11 Becton, Dickinson And Company Sequences and methods for detecting influenza a and influenza b virus
US8354230B2 (en) * 2007-12-21 2013-01-15 Quest Diagnostics Investments Inc. Multiplex detection assay for influenza and RSV viruses
CN102170902B (zh) 2008-08-01 2015-07-15 伽玛疫苗有限公司 流感疫苗
WO2010127252A2 (en) * 2009-04-30 2010-11-04 Vanderbilt University Monoclonal antibodies to influenza h1n1 virus and uses thereof
SG168423A1 (en) * 2009-07-13 2011-02-28 Agency Science Tech & Res Influenza detection method and kit therefor
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
WO2013033092A2 (en) 2011-09-03 2013-03-07 Boehringer Ingelheim Vetmedica Gmbh Streptococcus suis pilus antigens
EP2846825B1 (en) 2012-03-14 2021-05-05 The Regents of The University of California Treatment of inflammatory disorders in non-human mammals
ES2689878T3 (es) 2013-02-21 2018-11-16 Boehringer Ingelheim Vetmedica Gmbh Proteínas H5 del virus de la gripe H5N1 para su uso como un medicamento
CN105143251B (zh) * 2013-03-18 2021-05-11 奥西瓦科斯公司 流感核蛋白疫苗
EP4091629A1 (en) 2013-09-25 2022-11-23 Zoetis Services LLC Pcv2b divergent vaccine composition and methods of use
AU2015241107B2 (en) 2014-04-03 2019-10-03 Boehringer Ingelheim Animal Health USA Inc. Porcine epidemic diarrhea virus vaccine
JP7046607B2 (ja) 2015-08-31 2022-04-04 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 先天性振戦に対するペスチウイルスワクチン
MX2018003173A (es) 2015-09-16 2018-05-17 Boehringer Ingelheim Vetmedica Inc Vacunas de salmonella choleraesuis-salmonella typhimurium.
HUE064133T2 (hu) 2016-09-20 2024-03-28 Boehringer Ingelheim Vetmedica Gmbh Kutya adenovírus vektor
WO2018054822A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh New swine influenza vaccine
AR109539A1 (es) 2016-09-20 2018-12-19 Boehringer Ingelheim Vetmedica Gmbh Sitio de inserción orf70 de ehv
JP7187448B2 (ja) 2016-09-20 2022-12-12 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 新しいプロモーター
RS67051B1 (sr) 2016-11-03 2025-08-29 Boehringer Ingelheim Vetmedica Gmbh Vakcina protiv svinjskog parvovirusa
ES2942749T3 (es) 2016-11-03 2023-06-06 Boehringer Ingelheim Vetmedica Gmbh Vacuna contra el parvovirus porcino y el virus del síndrome reproductivo y respiratorio porcino, y métodos de producción de la misma
EP3573655A2 (en) 2017-01-30 2019-12-04 Boehringer Ingelheim Animal Health USA Inc. Porcine coronavirus vaccines
EP3651797A1 (en) 2017-07-12 2020-05-20 Boehringer Ingelheim Animal Health USA Inc. Senecavirus a immunogenic compositions and methods thereof
EA202090628A1 (ru) 2017-09-23 2020-11-16 Бёрингер Ингельхайм Ветмедика Гмбх Система экспрессии paramyxoviridae
WO2019092027A1 (en) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
EP3668988B1 (en) 2018-02-23 2025-07-23 Boehringer Ingelheim Vetmedica GmbH Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom
EP3768307A1 (en) 2018-03-19 2021-01-27 Boehringer Ingelheim Vetmedica GmbH New ehv with inactivated ul18 and/or ul8
AU2019239552A1 (en) 2018-03-19 2020-09-10 Boehringer Ingelheim Vetmedica Gmbh EHV insertion site UL43
TW202003027A (zh) 2018-03-26 2020-01-16 美商百靈佳殷格翰動物保健美國有限公司 製造免疫原組合物之方法
EP3852800A1 (en) 2018-09-20 2021-07-28 Boehringer Ingelheim Vetmedica GmbH Intranasal vector vaccine against porcine epidemic diarrhea
WO2020058327A1 (en) 2018-09-20 2020-03-26 Boehringer Ingelheim Vetmedica Gmbh Modified pedv spike protein
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi
JP7802674B2 (ja) 2020-02-06 2026-01-20 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 抗ラブドウイルス抗体を検出するのに有用なポリペプチド
JP7737447B2 (ja) 2020-10-05 2025-09-10 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド サーコウイルス科カプシドタンパク質を含む融合タンパク質、及びそれから構成されるキメラウイルス様粒子
US20220160866A1 (en) 2020-10-05 2022-05-26 Boehringer Ingelheim Vetmedica Gmbh Fusion protein useful for vaccination against rotavirus
AU2023251268A1 (en) 2022-04-05 2024-11-14 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition useful for vaccination against rotavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86354A0 (en) * 1987-05-22 1988-11-15 Orion Yhtymae Oy Episomal vector for the expression of selected dna fragments coding for optional polypeptides in mammalian cells and methods for the production thereof
DK0737750T3 (da) * 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit

Also Published As

Publication number Publication date
PL178626B1 (pl) 2000-05-31
CZ237395A3 (en) 1996-02-14
EP0620277A1 (en) 1994-10-19
SK114295A3 (en) 1996-02-07
YU12894A (sh) 1997-12-05
AU5788994A (en) 1994-09-22
FI954329A0 (fi) 1995-09-14
CA2119175A1 (en) 1994-09-19
BG100006A (bg) 1996-12-31
JP3608642B2 (ja) 2005-01-12
NO953649D0 (no) 1995-09-15
NZ263680A (en) 1997-05-26
PL310677A1 (en) 1995-12-27
DZ1759A1 (fr) 2002-02-17
UA42715C2 (uk) 2001-11-15
FI954329A7 (fi) 1995-09-14
HU9502702D0 (en) 1995-11-28
CN1119458A (zh) 1996-03-27
JPH0795888A (ja) 1995-04-11
BG63126B1 (bg) 2001-04-30
IL108915A0 (en) 1994-06-24
WO1994021797A1 (en) 1994-09-29
HRP940175A2 (en) 1997-04-30
HUT73397A (en) 1996-07-29
SI9420014A (en) 1996-08-31
JPH10113194A (ja) 1998-05-06
RO117710B1 (ro) 2002-06-28
FI954329L (fi) 1995-09-14
CZ290315B6 (cs) 2002-07-17
NO953649L (no) 1995-11-17
JP2812352B2 (ja) 1998-10-22
AU676258B2 (en) 1997-03-06

Similar Documents

Publication Publication Date Title
BR9406007A (pt) Construção de DNA, vacina de polinucleotídeos, vetor, processos para proteger contra infecção por vírus influenza humano, para usar um gene de vírus influenza, para induzir respostas imunes contra infecção ou doença provocada por cepas de vírus influenza, composição de construções de ácido nucleico e uso de um gene de vírus influenza humano
ATE342916T1 (de) Synthetische hiv gag gene
HUP9901112A2 (hu) Szintetikus HIV-gének
HUP9903822A2 (hu) Polinukleotid-vakcinakészítmény sertések szaporodásbiológiai és légzőszervi kórképei ellen
EP1200109A4 (en) USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
EP1016418A3 (en) Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
ES2151506T3 (es) Moleculas de adn recombinante que codifican enzimas aminopeptidasa y su uso en la preparacion de vacunas contra infecciones por helmintos.
HUP0402259A2 (hu) Vakcinák
PT1212358E (pt) Genes sinteticos de papilomavirus humano
WO2000066739A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
Qiao et al. Vaccines developed for H5 highly pathogenic avian influenza in China
BR0316291A (pt) Vacina contra hcv, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina contra hcv
DE69732029D1 (de) Dna enthaltende impfstoffen
BR9509076A (pt) Molécula de dna isolada e purificada vetor de expressão proteína anticorpo monoespecífico composto composição farmacêutica vacina e processos para expressar preteina de papilomavírus humano tipo 6a para identificar compostos e para induzir respostas imunes contra infecção ou doença provocada por papilomavírus humano
MXPA02005506A (es) Clonacion de un gen que codifica una racemasa de aminoacido derivada de tripanosoma cruzi, y usos del mismo.
DE60117053D1 (de) Herstellung rekombinanter künstlicher hefe-chromosome, welche das genom des humanen cytomegalovirus enthalten
BR9707400A (pt) Vacinas contra produto do gene 63 de vìrus varicella zoster.
Palese et al. Structure, Genetic structure and genetic variation of influenza viruses
Tempesta et al. A classical inactivated vaccine induces protection against caprine herpesvirus 1 infection in goats
NO965017D0 (no) Oligonukleotider med anti-cytomegalovirus aktivitet
MY101874A (en) Vaccine
ATE417106T1 (de) Chlamydia antigene und deren korrespondierende dna fragmente und verwendungen davon
WO1998052603A3 (en) An influenza enveloped dna vaccine

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal